Daily Cardiology Research Analysis
Analyzed 57 papers and selected 3 impactful papers.
Summary
Three impactful cardiology studies stood out today: a mechanistic Nature Communications study identifies a MARCH2–NR1H2 (LXRβ) axis in cardiac macrophages that prevents doxorubicin-induced cardiomyopathy by enhancing efferocytosis; a Europace analysis links day-to-day C-reactive protein fluctuations with atrial fibrillation episodes; and a prospective JACC Advances study shows that age- and biopsy-guided screening during carpal tunnel surgery detects early-stage ATTR-CM at meaningful yield.
Research Themes
- Cardio-oncology mechanisms: macrophage efferocytosis and anthracycline cardiotoxicity
- Inflammation as an acute trigger for atrial fibrillation
- Opportunistic screening for transthyretin cardiac amyloidosis during carpal tunnel surgery
Selected Articles
1. MARCH2 prevents doxorubicin-induced cardiomyopathy by stabilizing NR1H2 and promoting clearance of apoptotic cardiomyocytes.
This preclinical study identifies the MARCH2–NR1H2 (LXRβ) pathway in cardiac macrophages as a key regulator of efferocytosis that protects against doxorubicin-induced cardiomyopathy. MARCH2 expression was reduced in DiCM mice and human DCM macrophages; genetic disruption of MARCH2 impaired apoptotic cell clearance, whereas stabilizing NR1H2 restored efferocytosis and mitigated cardiotoxicity.
Impact: Reveals a druggable macrophage pathway linking efferocytosis to anthracycline cardiotoxicity, opening a new strategy in cardio-oncology beyond cardiomyocyte-targeted protection.
Clinical Implications: Suggests that enhancing macrophage efferocytosis via MARCH2–NR1H2 could prevent or lessen anthracycline cardiomyopathy; motivates development of LXRβ stabilizers or MARCH2 agonists alongside guideline cardioprotection.
Key Findings
- MARCH2 expression is reduced in cardiac macrophages from DiCM mice and human dilated cardiomyopathy patients.
- MARCH2 disruption impairs efferocytosis and exacerbates doxorubicin cardiotoxicity; stabilizing NR1H2 (LXRβ) restores apoptotic cell clearance.
- Identifies a macrophage MARCH2–NR1H2 axis as a central regulator of efferocytosis in DiCM.
Methodological Strengths
- Mechanistic dissection across species with in vivo and human tissue data
- Target-pathway linkage (MARCH2 to NR1H2/LXRβ) with functional rescue
Limitations
- Preclinical evidence; clinical translatability and safety of pathway modulation remain untested.
- Abstracted details on experimental design and sample sizes are limited in the available text.
Future Directions: Develop selective MARCH2 activators or LXRβ-stabilizing agents; test macrophage-targeted delivery; validate efferocytosis biomarkers and cardioprotection in early-phase cardio-oncology trials.
Doxorubicin-induced cardiomyopathy (DiCM) involves impaired clearance of apoptotic cardiomyocytes (efferocytosis) by cardiac macrophages. This study reveals a central role for the MARCH2-NR1H2 axis in this process. We find that MARCH2 expression is significantly reduced in cardiac macrophages from DiCM mice and human dilated cardiomyopathy patients. Genetic ablation of MARCH2, either globally (MARCH2
2. Inflammation and day-to-day occurrence of atrial fibrillation.
Linking >1.2 million ILR-monitored person-days to >7,000 CRP measurements, the study shows that daily CRP levels are higher on AF days and that each CRP doubling increases AF odds by 36%. A dose–response pattern was evident, with CRP >10 mg/L markedly increasing AF incidence in self-controlled analyses, supporting inflammation as an acute AF trigger.
Impact: Provides rare day-level temporal evidence connecting systemic inflammation to AF episodes, informing biomarker-guided risk prediction and interventional trial design.
Clinical Implications: CRP could aid dynamic AF risk stratification and trigger-based management (e.g., intensified rhythm monitoring, anti-inflammatory strategies) during inflammatory flares.
Key Findings
- Across 1,065 participants, CRP was higher on AF days (8.37 vs 4.02 mg/L).
- Each doubling of CRP was associated with 36% higher AF odds (aOR 1.36; 95% CI 1.26-1.47).
- CRP >10–50 mg/L and >50 mg/L increased AF odds (aOR 3.50 and 5.75, respectively); SCCS IRR for CRP >10 mg/L was 2.41.
Methodological Strengths
- Continuous implantable loop recorder monitoring linked with contemporaneous CRP sampling
- Multiple analytic approaches including self-controlled case series and mixed models demonstrating dose–response
Limitations
- Post-hoc observational design with potential residual confounding and selection bias.
- CRP sampling was intermittent and episodes <60 minutes were not captured.
Future Directions: Test anti-inflammatory interventions or CRP-guided monitoring to reduce AF burden; evaluate other inflammatory biomarkers and causal pathways.
BACKGROUND AND AIMS: Inflammation is central in atrial fibrillation (AF) pathophysiology, but the temporal association between inflammatory activity and AF remains uncertain. This study investigated the day-to-day relationship between plasma C-reactive protein (CRP) levels and AF occurrence in continuously monitored individuals. METHODS: Post-hoc analysis of the LOOP study randomizing participants with stroke risk factors to implantable loop recorder (ILR) screening (n=1501) or usual care. ILR raw data were linked to blood samples collected within one day. The outcome was AF episodes lasting ≥60 minutes. Associations were examined using generalized and linear mixed models and as a self-controlled case series (SCCS). RESULTS: ILR and CRP data were available for 1065 participants combining >1.2 million days of heart rhythm monitoring (including ∼40,000 days with AF) with >7,000 CRP measurements. CRP was higher during days with AF (geometric mean 8.37 [7.11-9.86] mg/L) versus non-AF days (4.02 [3.71-4.35] mg/L). Each doubling of CRP was associated with 36% higher odds of AF (adjusted odds ratio [aOR] 1.36 [1.26-1.47]). Compared with CRP ≤3 mg/L, the odds of AF increased for CRP >10-50 mg/L and >50 mg/L (aOR 3.50 [2.18-5.60] and 5.75 [3.48-9.50], respectively). In SCCS analyses, CRP >10 mg/L was associated with higher incidence of AF compared to lower levels (incidence rate ratio 2.41 [1.53-3.80]). CONCLUSIONS: This exploratory study found a temporal and dose-response relationship between CRP levels and AF occurrence, supporting inflammation as an acute trigger and underscoring the need to evaluate inflammatory markers as potential targets in AF management.
3. Early Diagnosis of ATTR-CM by Age- and Carpal Tunnel Biopsy-Guided Screening.
In men ≥65 and women ≥75 undergoing CTS surgery, 56% had carpal tenosynovial amyloid deposition; among those fully evaluated, 17.3% had ATTR-CM, predominantly early-stage. Screening-detected cases had milder disease than contemporary clinically diagnosed patients, supporting opportunistic, age- and biopsy-guided screening.
Impact: Demonstrates a pragmatic pathway for earlier ATTR-CM diagnosis at the point of CTS surgery, when disease burden is low and treatment may be most effective.
Clinical Implications: Surgeons and cardiologists can integrate age- and biopsy-guided screening during CTS surgery to identify early-stage ATTR-CM, enabling timely disease-modifying therapy and structured follow-up.
Key Findings
- Tenosynovial amyloid was present in 61/109 (56.0%) CTS patients screened.
- Among amyloid-positive patients completing cardiac workup, 9/52 (17.3%) had ATTR-CM; 89% were NAC stage I.
- Screening-detected ATTR-CM cases were milder than clinically diagnosed contemporary controls.
Methodological Strengths
- Prospective, multicenter design with predefined age criteria and biopsy confirmation
- Standardized downstream cardiac workup and comparison with contemporary clinical cohort
Limitations
- Sample size is modest and only 52/61 amyloid-positive patients completed full cardiac evaluation.
- Generalizability may be limited to centers with coordinated cardio-orthopedic pathways.
Future Directions: Validate in larger, diverse CTS populations; assess cost-effectiveness and outcomes with early tafamidis initiation; refine selection criteria beyond age alone.
BACKGROUND: Transthyretin amyloid cardiomyopathy (ATTR-CM) is frequently preceded by carpal tunnel syndrome (CTS). The value of age- and biopsy-guided screening during CTS surgery for early detection of ATTR-CM remains uncertain. OBJECTIVES: We aimed to determine the proportion of amyloid deposition in tenosynovial biopsies, the proportion of ATTR-CM among biopsy-positive patients, and to compare disease severity between screening-detected and clinically diagnosed ATTR-CM patients. METHODS: This prospective, multicenter cohort study enrolled men ≥65 and women ≥75 years undergoing surgery for idiopathic CTS and analyzed tenosynovial biopsies for amyloid deposition. Patients with amyloid-positive biopsies underwent cardiac workup, including echocardiography, bone scintigraphy, biomarker testing, and genetic testing to confirm ATTR-CM. A control cohort of contemporary clinically diagnosed wildtype ATTR-CM patients was included for comparison. RESULTS: In total, 109 CTS patients were included (median age 79 years [IQR: 75-82]). Tenosynovial amyloid deposition was detected in 61/109 patients (56.0%; 95% CI: 46.1-65.5), of whom 52/61 patients completed cardiac evaluation. ATTR-CM was diagnosed in 9/52 patients (17.3%; 95% CI: 8.2-30.3; median age 83 years [IQR: 80-84]; male-to-female ratio 3.5:1; n = 7/2). Patients identified through screening had milder disease, 8/9 (89%) were in the National Amyloidosis Centre stage I compared to 26/47 (55%) among clinically diagnosed patients. CONCLUSIONS: Systematic age- and biopsy-guided screening during CTS surgery identified a high proportion of carpal amyloid deposition. Among amyloid-positive CTS patients, 1 in 6 was diagnosed with early-stage ATTR-CM. This approach demonstrated a higher yield in identifying ATTR-CM with mild disease burden and may serve as a tool for earlier diagnosis.